Development asset linked to Betta Pharmaceuticals Co in public FDA and regional records.
pharma · Psoriasis · EGFR Positive Non-small Cell Lung Cancer
Betta Pharmaceuticals Co
Betta Pharmaceuticals Co.,
Betta Pharmaceuticals Co drug portfolio — 4 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Hangzhou, CN HQ
23 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Hangzhou, CN
- Employees
- 23
- Programs
- 2
- Drugs
- 4
- Patents
- 0
Betta Pharmaceuticals Co pipeline
Portfolio lens on 4 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Betta Pharmaceuticals Co drug portfolio — 4 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Betta Pharmaceuticals Co in public FDA and regional records.
-
Development asset linked to Betta Pharmaceuticals Co in public FDA and regional records. Molecular target: Epidermal growth factor receptor.
- Target
- Epidermal growth factor receptor
- Mechanism
- Epidermal growth factor receptor erbB1 inhibitor
-
Development asset linked to Betta Pharmaceuticals Co in public FDA and regional records.